Connect with us
Finance Digest is a leading online platform for finance and business news, providing insights on banking, finance, technology, investing,trading, insurance, fintech, and more. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.
Research Reports

The global demand for stent graft balloon catheter will register a healthy expansion during 2017 to 2022. Revenues from the market are expected to surpass US$ 1,000 Mn by the end of 2022. Usually utilized in bypass graft surgery as…

The post Sales of Stent Graft Balloon Catheter In Cardiac Catheterization Laboratories are Expected to Surpass US$ 1,000 Mn by the End of 2022 appeared first on The Tribune City.

Sales of Stent Graft Balloon Catheter In Cardiac Catheterization Laboratories are Expected to Surpass US$ 1,000 Mn by the End of 2022

Published On :

The global demand for stent graft balloon catheter will register a healthy expansion during 2017 to 2022. Revenues from the market are expected to surpass US$ 1,000 Mn by the end of 2022.

Usually utilized in bypass graft surgery as well as balloon angioplasty, stent graft balloon catheters prevent risks concerning occurrence of re-narrowing in patients undergoing angioplasty, and risks related to abrupt artery closure. Owing to these advantages offered by stent graft balloon catheters, their demand is witnessing a rise. A gradual evolution has been observed in the stent graft balloon catheter market, from the simple stents to modification of balloon stent catheters. Since recent past, there has been a surge in hospital admissions caused by increasing cases of atherosclerosis, and soaring prevalence of CAD – coronary artery disease globally. Numerous developments have been realized in technology of balloon catheters, along with the hike in healthcare expenditure. These factors are expected to augment growth of the market. In contrast, high prices of angioplasty procedures has become a problem for population across developing and underdeveloped economies. This might act as an impeding factor for the market growth.

Growth of the global stent graft balloon catheter market has been highly favored by the advent of drug eluting balloons. In addition, shifting preferences towards using balloons with drug delivery, and helping to deliver medications at local sites, has deemed them to be effective substitutes for administering drugs intravenously. Various new products developed are being approved for treatment of vascular diseases. For instance – recently, the FDA has approved use of expandable balloon stent graft introduced by the W.L. Gore & Associates to treat peripheral artery disease. Moreover, technology advancements in the stent graft balloon catheters, coupled with increasing awareness about angioplasty, and sophisticated healthcare infrastructure in developed economies are further poised to drive the market growth in the near future.

Market Taxonomy

Indication
  • Coronary Artery Disease
  • Peripheral Vascular Disease
End User
  • Hospitals
  • Ambulatory Surgical Centers
  • Cardiac Catheterization Laboratories
Raw Material
  • Polyurethane
  • Nylon
  • Others

9 Key Estimations from Fact.MR’s Report on the Global Stent Graft Balloon Catheter Market

  1. Based on raw material, sales of polyurethane for producing stent graft balloon catheters will register a steady expansion, while sales of nylon are estimated to register a sluggish growth through 2022.
  2. Cardiac catheterization laboratories are anticipated to become the fastest growing end-users in the global stent graft balloon catheter market.
  3. Ambulatory surgical centres are expected to be the least lucrative end-users of stent graft balloon catheters.
  4. Hospitals will continue to be the largest end-user segment, with sales poised to reach nearly US$ 900 Mn by 2022-end.
  5. Sales of stent graft balloon catheters for coronary artery disease indication are projected to account for over two-third share of the market over the forecast period, in terms of revenues.
  6. Demand for stent graft balloon catheters from peripheral vascular disease indication segment will remain sluggish in the market.
  7. Although, the market in Middle East & Africa (MEA) is expected to register a sluggish expansion, sales of stent graft balloon catheter in this region are estimated to gain an uptick by 2022-end.
  8. Europe will continue to be the largest market for stent graft balloon catheter, with sales projected to exceed US$ 400 Mn in revenues by 2022-end.Key players contributing to growth of the marketMeril Life Sciences Pvt. Ltd. Abbott Laboratories, Hexacath, Cardionovum GmbH, Jotech GmbH, MicroPort Scientific Corporation, Boston Scientific Corporation, Terumo Corporation, Cook Medical INC, B. Braun Melsungen AG, Cordis Corporation, and Medtronic Plc.

For More Insights

https://www.biospace.com/article/unhealthy-lifestyle-habits-and-improving-awareness-about-new-therapeutics-are-two-key-factors-driving-osteopenia-treatment-market-growth-notes-fact-mr/

About Us:

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.

Contact:

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
Email: sales@factmr.com
Visit Our Website: https://www.factmr.com

The post Sales of Stent Graft Balloon Catheter In Cardiac Catheterization Laboratories are Expected to Surpass US$ 1,000 Mn by the End of 2022 appeared first on The Tribune City.

Luigi Wewege

Luigi Wewege is the Senior Vice President, and Head of Private Banking of Belize based Caye International Bank, a FinTech School Instructor and the published author of The Digital Banking Revolution – now in its third edition. You can follow his posts on trends shaping the banking and financial services industry on Twitter: @luigiwewege

Continue Reading

Why pay for news and opinions when you can get them for free?

       Subscribe for free now!


By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Recent Posts